Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs.
Tumour necrosis factor alpha inhibitors, both infliximab and adalimumab, have been approved for the treatment of both rheumatoid arthritis and Crohn's disease. A slight increase in the risk of infections in patients receiving immunosuppressants and/or biological agents has been reported. Here, we present the case of a 68-year-old woman affected by Crohn's disease, myasthenia gravis, recurrent uveitis and rheumatoid arthritis who developed pneumonia during concomitant treatment with biological agents and conventional immunosuppressive drugs.
Angelucci
Erika
E
Gastroenterology Unit, University of Rome Sapienza, Viale del Policlinico 155, 00161, Rome, Italy. erika.angelucci@yahoo.it
Cesarini
Monica
M
Vernia
Piero
P
D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001379:Azathioprine / Q000009:adverse effects; D019818:Clavulanic Acid / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069285:Infliximab; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011014:Pneumonia / Q000188:drug therapy / Q000276:immunology*; D011239:Prednisolone / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D019818:Clavulanic Acid; D000658:Amoxicillin; D011239:Prednisolone; D000069285:Infliximab; D001379:Azathioprine